ClinicalTrials.gg
Active, not recruitingNCT05031780Updated Oct 26, 2026

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

A Phase 2/3 interventional study of Mitapivat and Mitapivat-matching placebo in Sickle Cell Disease, sponsored by Agios Pharmaceuticals, Inc.. Active, not recruiting at 91 sites in 16 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
33rd of 559
286 · median 31
Started
2022
with 40 others
Phase 2/3
7 of 733
1 open now
Primary completion
2025-10
later than 19 of 182 live
Registered
560th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 33rd largest by enrollment of the 559 interventional ones that give a count, is one of 41 that started in 2022, is one of 7 in phase 2/3, reaches primary completion later than 19 of the 182 other live ones, and was the 560th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in sickle cell disease by testing how well mitapivat works compared to placebo to increase the amount of hemoglobin in the blood and to reduce or prevent the occurrence of sickle cell pain crises. In addition, the long-term effect of mitapivat on efficacy and safety will be explored in an open-label extension portion.

Read the detailed description

Mitapivat is a small molecule, oral activator of pyruvate kinase R (PKR). PKR is involved with maintaining health, energy, and longevity of red blood cells (RBCs). The study aims to evaluate the efficacy and safety of treatment with mitapivat in participants with sickle cell disease. The study is a Phase 2/3 study in which the recommended dose of mitapivat will be selected and further evaluated. The Phase 2 portion includes a 12-week randomized, placebo-controlled period in which participants will be randomized in a 1:1:1 ratio to receive 2 dose levels of mitapivat or placebo. The Phase 3 portion includes a 52-week randomized, placebo-controlled period in which participants will be randomized in a 2:1 ratio to receive the recommended mitapivat dose level or placebo. Participants who complete either the Phase 2 or Phase 3 portion will have the option to move into a 216-week open label extension period to receive mitapivat.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 16 years or older (18 years or older [France and Germany]); participants age 16 or 17 years must physically have completed puberty;
  • Documented diagnosis of sickle cell disease (SCD) (HbSS, HbSC [combined heterozygosity for hemoglobins S and C], HbS/beta 0- thalassemia, HbS/ beta plus thalassemia, or other sickle cell syndrome variants);
  • At least 2 SCPCs and no more than 10 SCPCs in the past 12 months;
  • at least 5.5 and 10.5 gram per deciliter (g/dL) at the most. Hemoglobin concentration must be based on an average of at least 2 Hb concentration measurements (separated by ≥7 days) collected during the Screening Period;
  • If taking hydroxyurea, the hydroxyurea dose must be stable for at least 90 days before starting study drug. Discontinuation of hydroxyurea requires a 90-day prior to informed assent/consent;
  • Women capable of becoming pregnant must agree to use 2 forms of .

Exclusion criteria

Exclusion Criteria:

  • Pregnant, breastfeeding, or parturient;
  • Receiving regularly scheduled transfusions;
  • Hepatobiliary disorders including but not limited to significant liver disease or gallbladder disease;
  • Severe kidney disease;
  • Prior exposure to gene therapy or prior bone marrow or stem cell transplantation;
  • Currently receiving treatment with a disease-modifying therapy for SCD (eg, voxelotor, crizanlizumab, L-glutamine), with the exception of hydroxyurea. The last dose of voxelotor, crizanlizumab, and L-glutamine must have been administered at least 90 days before randomization;
  • Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered at least 90 days before starting study drug;
  • Received treatment on another trial within 90 days prior to start of study drug or plans to participate in another investigational drug trial;
  • Taking medications that are strong inhibitors of /5 or strong inducers of CYP3A4 that cannot be stopped in an acceptable timeframe before starting study drug (timeframe will be discussed with your doctor).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
286 participants (actual)

Study arms

  • Experimental
    Phase 2: Mitapivat 50 mg BID

    Double-blind Period: Mitapivat 50 milligrams (mg) twice daily (BID) for 12 weeks.

    Drug: Mitapivat

  • Experimental
    Phase 2: Mitapivat 100 mg BID

    Double-blind Period: Mitapivat 100 mg BID for 12 weeks.

    Drug: Mitapivat

  • Placebo comparator
    Phase 2: Placebo

    Double-blind Period: Mitapivat-matching placebo for 12 weeks.

    Other: Mitapivat-matching placebo

  • Experimental
    Phase 2: Open-Label Extension Period

    Participants who received mitapivat 50mg BID in the double-blind period may choose to receive mitapivat 50mg BID for 216 weeks after. Participants who received mitapivat 100mg BID in the double-blind period may choose to receive mitapivat 100 mg BID for 216 weeks after. Participants who received mitapivat-matching placebo in the double-blind period, may be randomized to receive either mitapivat 50 mg or 100 mg BID for 216 weeks after.

    Drug: Mitapivat

  • Experimental
    Phase 3: Mitapivat 100 mg BID

    Double-blind Period: Mitapivat 100 mg BID for 52 weeks.

    Drug: Mitapivat

  • Placebo comparator
    Phase 3: Placebo

    Double-blind Period: Mitapivat-matching placebo for 52 weeks.

    Other: Mitapivat-matching placebo

  • Experimental
    Phase 3: Open-Label Extension Period

    Participants may choose to receive mitapivat 100 mg BID for 216 weeks after the Double-blind Period. Participants who received mitapivat-matching placebo in the double-blind period, may choose to receive mitapivat 100 mg BID for 216 weeks after the Double-blind Period.

    Drug: Mitapivat

Interventions

  • Mitapivat tablets

    Also known as: AG-348, Mitapivat Sulfate

  • OtherMitapivat-matching placebo

    Placebo to match 50 mg or 100 mg tablets

  • OtherMitapivat-matching placebo

    Placebo to match 100 mg tablets

06

What researchers measure

Primary outcomes

  1. Phase 2: Percentage of Participants With Hemoglobin (Hb) Response

    Time frame: Week 12

  2. Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious AEs (SAEs)

    Time frame: Up to Week 12

  3. Phase 3: Percentage of Participants With Hb Response

    Time frame: Week 52

  4. Phase 3: Annualized Rate of Sickle Cell Pain Crises (SCPCs)

    Time frame: Up to Week 52

Secondary outcomes

  1. Phase 2: Change From Baseline in Hb Concentration

    Time frame: Baseline, Week 10 up to Week 12

  2. Phase 2: Change From Baseline in Indirect Bilirubin

    Time frame: Baseline, Week 10 up to Week 12

  3. Phase 2: Change From Baseline in Lactate Dehydrogenase (LDH)

    Time frame: Baseline, Week 10 up to Week 12

  4. Phase 2: Change From Baseline in Absolute Reticulocytes Count

    Time frame: Baseline, Week 10 up to Week 12

  5. Phase 2: Change From Baseline in Percent Reticulocytes

    Time frame: Baseline, Week 10 up to Week 12

  6. Phase 2: Change From Baseline in Erythropoietin

    Time frame: Baseline, Week 10 up to Week 12

  7. Phase 2: Change From Baseline in Patient-Reported Outcomes Measurement Information System® (PROMIS®) Fatigue 13a Short Form (SF) Score

    Time frame: Baseline, Week 10 up to Week 12

  8. Phase 2: Annualized Rate of SCPCs

    Time frame: Up to Week 12

  9. Phase 2: Pharmacokinetic/Pharmacodynamic Relationship: Evaluate the Exposure of Mitapivat to the Change in Adenosine Triphosphate (ATP) and 2,3-Diphosphoglycerate (2,3-DPG)

    Time frame: Day 1 up to Week 8

  10. Phase 2: Mitapivat Concentration Over Time

    Time frame: Day 1 up to Week 8

  11. Phase 2: Mitapivat Area Under the Concentration

    Time frame: Day 1 up to Week 8

  12. Phase 2: Mitapivat Maximum (Peak) Concentration

    Time frame: Day 1 up to Week 8

  13. Phase 3: Change From Baseline in Hb Concentration

    Time frame: Baseline, Week 24 up to Week 52

  14. Phase 3: Change From Baseline in Indirect Bilirubin

    Time frame: Baseline, Week 24 up to Week 52

  15. Phase 3: Change From Baseline in Percent Reticulocytes

    Time frame: Baseline, Week 24 up to Week 52

  16. Phase 3: Change From Baseline in PROMIS® Fatigue 13a SF Scores

    Time frame: Baseline, Week 24 up to Week 52

  17. Phase 3: Annualized Frequency of Hospitalizations for SCPC

    Time frame: Up to Week 52

  18. Phase 3: Change From Baseline in LDH Concentration

    Time frame: Baseline, Week 24 up to Week 52

  19. Phase 3: Change From Baseline in Absolute Reticulocytes

    Time frame: Baseline, Week 24 up to Week 52

  20. Phase 3: Change From Baseline in Erythropoietin

    Time frame: Baseline, Week 24 up to Week 52

  21. Phase 3: Percentage of Participants With Improvement in the Patient Global Impression of Severity (PGIS) -Fatigue

    Time frame: Baseline, Weeks 24, 28, 40, and 52

  22. Phase 3: Percentage of Participants With Improvement in the Patient Global Impression of Change (PGIC) -Fatigue

    Time frame: Baseline, Weeks 24, 28, 40, and 52

  23. Phase 3: Time to First SCPC

    Time frame: Up to Week 52

  24. Phase 3: Time to Second SCPC

    Time frame: Up to Week 52

  25. Phase 3: Annualized Rate of Hospitalization Days for SCPC

    Time frame: Up to Week 52

  26. Phase 3: Annualized Rate of Emergency Room Visits for SCPC

    Time frame: Up to Week 52

  27. Phase 3: Change From Baseline in 6-Minute Walk Test (6MWT)

    Time frame: Baseline, Week 52

  28. Phase 3: Change From Baseline in PROMIS Pain Intensity

    Time frame: Baseline, Week 24 and 52

  29. Phase 3: Change From Baseline in Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) Pain Impact

    Time frame: Baseline, Week 24 and 52

  30. Phase 3: PGIC of Pain

    Time frame: Baseline, Week 52

  31. Phase 3: Change From Baseline in PGIS of Pain

    Time frame: Baseline, Week 52

  32. Phase 3: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious AEs (SAEs)

    Time frame: Up to 56 weeks

  33. Phase 3: Pharmacokinetic/Pharmacodynamic Relationship: Evaluate the Exposure of Mitapivat to the Change in ATP and 2,3-DPG Levels

    Time frame: Day 1 up to Week 40

  34. Phase 3: Mitapivat Concentration Over Time

    Time frame: Day 1 up to Week 40

  35. Phase 3: Mitapivat Area Under the Concentration Curve

    Time frame: Day 1 up to Week 40

  36. Phase 3: Mitapivat Maximum (Peak) Concentration

    Time frame: Day 1 up to Week 40

07

Study locations

91 sites
08

References and documents

Publications

  • Andemariam B, Kuo KHM, Algahtani FH, Al Kindi S, Ataga KI, Bartolucci P, Campbell A, Colombatti R, Glaros AK, Hafraoui K, Idowu M, Jacob SA, Lobo CLC, Nnodu OE, Otieno L, Smith WR, Thein SL, van Beers EJ, Gheuens S, Hensley B, Oluyadi A, Osman K, Pathan A, Patil S, Song T, Yates AM, Zaidi AU, Minniti C, Abboud MR; RISE UP Investigators. Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial. Lancet. 2026 Oct 24;408(10565):1705-1716. doi: 10.1016/S0140-6736(26)01480-7. PubMed 42913682 ↗
  • Conrey A, Asomaning N, Frey I, Charles RP, Lovins D, Xu JZ, Mendez-Marti S, Le K, Kruah B, Li Q, Dunkelberger E, Cellmer T, Yates A, Wind-Rotolo M, Huston C, Jeffries N, Eaton WA, Thein SL. Long-term mitapivat treatment is safe and efficacious in patients with sickle cell disease. Blood Red Cells Iron. 2025 Sep;1(2):100014. doi: 10.1016/j.brci.2025.100014. Epub 2025 Sep 11. PubMed 41809202 ↗
  • Idowu M, Otieno L, Dumitriu B, Lobo CLC, Thein SL, Andemariam B, Nnodu OE, Inati A, Glaros AK, Bartolucci P, Colombatti R, Taher AT, Abboud MR, Darbari D, Ataga KI, Antmen AB, Kuo KHM, de Souza Medina S, Oluyadi A, Iyer V, Morris S, Yates AM, Shao H, Patil S, Urbstonaitis R, Zaidi AU, Gheuens S, Smith WR. Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial. Lancet Haematol. 2025 Jan;12(1):e35-e44. doi: 10.1016/S2352-3026(24)00319-3. Epub 2024 Dec 4. PubMed 39644907 ↗
  • van Dijk MJ, Rab MAE, van Oirschot BA, Bos J, Derichs C, Rijneveld AW, Cnossen MH, Nur E, Biemond BJ, Bartels M, Jans JJM, van Solinge WW, Schutgens REG, van Wijk R, van Beers EJ. One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study. Blood Adv. 2023 Dec 26;7(24):7539-7550. doi: 10.1182/bloodadvances.2023011477. PubMed 37934880 ↗
  • Obadina M, Wilson S, Derebail VK, Little J. Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations. Kidney360. 2023 Jul 1;4(7):997-1005. doi: 10.34067/KID.0000000000000162. Epub 2023 May 31. PubMed 37254256 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Oct 2025, 44 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Sep 2, 2021
StartActual
Feb 11, 2022
Primary completionActual
Oct 30, 2025
CompletionEst.
Feb 2030
Results delay requested
Oct 22, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42913682 ↗
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42913682 ↗
    + 3 other changes: verification date, registry dates and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05031780
Responsible party
Sponsor
First posted
Sep 2, 2021
Start date
Feb 11, 2022
Primary completion
Oct 30, 2025
Completion
Feb 2030 (estimated)
Last update
Oct 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitapivat

Start the discussion